Brean Murray Carret & Co. Downgrades Human Genome Sciences (HGSI) to Hold; Q3 Earnings Provide Little to be Enthusiastic About

Article Stock Quotes (1) Comments (0)

Brean Murray Carret & Co. downgraded Human Genome Sciences (NASDAQ: HGSI) from Buy to Hold.

Brean analyst says, "Benlysta sales came in at the low end of consensus expectations but in line with our own estimates. However, we believe the market will see mgmt's decision to push back the goal of profitability from 2013 to 2014 as a negative signal highlighting the company's own disappointment in the initial trajectory of Benlysta sales."

For more ratings news on Human Genome Sciences click here and for the rating history of Human Genome Sciences click here.

Shares of Human Genome Sciences closed at $12.73 yesterday, with a 52 week range of $10.40-$30.15.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Applied Materials, Inc. (AMAT) Tops Q2 EPS by 3c, Offers Guidance
• Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
• DA Davidson Downgrades Applied Materials (AMAT) to Neutral

Create E-mail Alert Related Categories

Downgrades

Related Entities

Brean Murray Carret & Co., Earnings

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?